Find the right fit for you - faster
Get tailored insights about working at TRANSGENE in one quick step.
TRANSGENE Snapshot
TRANSGENE's expertise in gene therapy may help it transform into a cancer fighter. The biotech company is focusing its research and development efforts on its two most promising cancer vaccine candidates. One uses two antigens from the human papillomavirus (HPV) to treat cervical cancer, while the other candidate targets breast, lung, prostate, lung, and other cancers. In addition to these two projects, TRANSGENE is developing two immune therapy adjuvants that are injected directly into tumors in addition to other cancer therapy products. Contract research and licensing revenues account for all of the company's profit. Chairman Christophe Mérieux and his family control 70% of TRANSGENE.
